Company Overview

Cardiff Oncology, Inc. is a clinical-stage biotechnology company focused on developing therapies for cancer treatment, with a primary emphasis on targeting polo-like kinase 1 (PLK1), a protein involved in tumor cell division and survival. The company operates within the oncology and biopharmaceutical industries and is publicly traded on Nasdaq under the ticker CRDF. Its core development program is onvansertib, an orally administered and highly selective PLK1 inhibitor being evaluated in combination therapies for several cancer indications, including metastatic colorectal cancer (mCRC), pancreatic cancer, and other solid tumors.

The company’s principal value driver is the advancement and commercialization potential of onvansertib through clinical development, strategic collaborations, and intellectual property associated with PLK1 inhibition. Cardiff Oncology has focused particularly on KRAS-mutated cancers, where unmet medical need remains significant despite recent advances in targeted therapies. The company originated as Trovagene, Inc., initially concentrating on molecular diagnostics before shifting its strategic focus toward oncology therapeutics through licensing and acquisition activities related to onvansertib. The company subsequently rebranded as Cardiff Oncology to reflect its therapeutic development orientation.

Business Operations

Cardiff Oncology’s operations are centered primarily around its oncology therapeutics development segment, with activities focused on clinical trials, regulatory advancement, biomarker research, and drug development partnerships. Revenue generation has historically been limited because the company remains in the clinical-stage phase and does not currently market approved commercial products. Operations are financed primarily through equity offerings, strategic financing activities, and collaborations. Clinical programs have included studies combining onvansertib with standard-of-care chemotherapy and targeted agents in colorectal and pancreatic cancer settings.

The company’s operational footprint includes clinical trial activity in the United States and selected international sites. Cardiff Oncology controls intellectual property related to onvansertib through licensing arrangements and patent portfolios associated with PLK1 inhibition technologies. The company has collaborated with academic cancer centers, contract research organizations, and pharmaceutical companies involved in combination treatment studies. Its development strategy relies heavily on precision oncology approaches using biomarker-defined patient populations, particularly those with KRAS mutations.

Strategic Position & Investments

Cardiff Oncology’s strategic direction is focused on advancing onvansertib through mid- and late-stage clinical development while demonstrating differentiated efficacy in genetically defined cancer populations. The company has concentrated investment toward expanding clinical data in metastatic colorectal cancer and evaluating combination regimens intended to improve treatment outcomes in resistant or refractory cancers. Management has emphasized a biomarker-driven development strategy intended to support targeted regulatory pathways and potentially accelerate commercialization opportunities.

The company’s most significant strategic asset is onvansertib, which was originally licensed from Nerviano Medical Sciences. Cardiff Oncology has invested substantially in clinical trial expansion, translational research, and companion biomarker analysis to strengthen its competitive position in precision oncology. The company has also explored opportunities involving combination therapies with established oncology treatments and emerging targeted therapies. Its strategic positioning is tied to the broader oncology trend toward personalized medicine and targeted inhibition of cell-cycle regulators.

Geographic Footprint

Cardiff Oncology is headquartered in San Diego, California, and primarily operates within the United States, although its clinical research activities extend internationally through multicenter trial participation. The company’s development programs involve collaborations with cancer treatment centers and research institutions across multiple geographic regions, particularly in North America and parts of Europe.

While Cardiff Oncology does not currently maintain a large global commercial infrastructure due to its clinical-stage status, its intellectual property, licensing arrangements, and clinical programs have international relevance. The company’s strategic and operational influence is primarily concentrated in oncology research markets with advanced clinical trial ecosystems and regulatory infrastructure.

Leadership & Governance

Cardiff Oncology’s leadership team is composed of biotechnology and pharmaceutical executives with experience in oncology drug development, clinical operations, and corporate finance. Governance oversight is provided by its board of directors, which includes individuals with backgrounds in biotechnology commercialization, medical research, and healthcare investment. Management has consistently emphasized disciplined clinical execution, biomarker-guided therapeutic development, and expansion of strategic oncology partnerships.

Key executives include:

• Mark Erlander – Chief Executive Officer
• James A. Breitmeyer, M.D., Ph.D. – President and Chief Medical Officer
• David A. Haen – Chief Financial Officer
• Fong Clow – Chief Business Officer
• Andrew McDonald, Ph.D. – Senior Vice President, Translational Sciences

The company’s leadership strategy has focused on advancing precision oncology programs through evidence-driven clinical development and leveraging scientific differentiation in PLK1 inhibition. Public disclosures in SEC filings and investor materials indicate that management prioritizes clinical validation, regulatory advancement, and capital efficiency as core elements of corporate strategy.